Asset Details
Do you wish to reserve the book?
Progress in molecular-based management of differentiated thyroid cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Progress in molecular-based management of differentiated thyroid cancer
Do you wish to request the book?
Progress in molecular-based management of differentiated thyroid cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Progress in molecular-based management of differentiated thyroid cancer
2013
Overview
Substantial developments have occurred in the past 5–10 years in clinical translational research of thyroid cancer. Diagnostic molecular markers, such as RET-PTC, RAS, and BRAFV600E mutations; galectin 3; and a new gene expression classifier, are outstanding examples that have improved diagnosis of thyroid nodules. BRAF mutation is a prognostic genetic marker that has improved risk stratification and hence tailored management of patients with thyroid cancer, including those with conventionally low risks. Novel molecular-targeted treatments hold great promise for radioiodine-refractory and surgically inoperable thyroid cancers as shown in clinical trials; such treatments are likely to become a component of the standard treatment regimen for patients with thyroid cancer in the near future. These novel molecular-based management strategies for thyroid nodules and thyroid cancer are the most exciting developments in this unprecedented era of molecular thyroid-cancer medicine.
Publisher
Elsevier Ltd,Elsevier,Elsevier Limited
Subject
Biological and medical sciences
/ Biopsy
/ Humans
/ Kinases
/ medicine
/ Molecular Targeted Therapy - methods
/ Molecular Targeted Therapy - trends
/ Mutation
/ Non tumoral diseases. Target tissue resistance. Benign neoplasms
/ patients
/ risk
/ Surgery
/ Thyroid
/ Thyroid Neoplasms - diagnosis
/ Thyroid Neoplasms - genetics
